News Sobi pays $1.5bn for Arthrosi to grow in gout Sobi has hit the acquisition trail with a deal to buy Arthrosi Therapeutics for up to $1.5 billion, adding a drug in late-stage testing for gout.
News Soufflé's tasty $200m raise, and other biofinancings New biotech financings include nine-figure rounds for Soufflé, Expedition, Arthrosi, and Nilo Therapeutics, with NanoPhoria and TORL not far behind.
News After setback, Rhythm gets good news on Imcivree from FDA Rhythm Pharma has secured the first approval in the US for a drug to treat hypothalamic obesity.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.